About Deep Light Vision

TECHNOLOGY FROM RESEARCH AT LUND UNIVERSITY

Deep Light Vision is driving the development of a new innovative medical imaging method called Ultrasound Optical Tomography (UOT). The research behind the technology has been ongoing for about ten years at the Department of Physics at Lund University and is led by Professor Stefan Kröll. As a result of the research, Deep Light Vision was formed in 2022 with the goal of commercializing the technology.

“The technology in Deep Light Vision is among the most exciting things I’ve seen in the technology companies I’ve worked with. I think it has the potential to become a ‘disruptive technology’, something completely new that can change the market and the use of medical imaging in medicine.” Johannes Swartling, CEO DLV

VISION - MOBILE EQUIPMENT FOR QUICK AND SIMPLE DIAGNOSTICS

Our vision is to introduce UOT as a new general medical imaging method in healthcare, alongside the established methods. Our goal is to provide a mobile device for quick and easy diagnostics in clinics and emergency departments worldwide.

The UOT technology has the potential to be used in suspected strokes and heart attacks, conditions where rapid diagnosis is crucial. The functional imaging also opens up the possibility of non-invasive or “digital” biopsy without physical sampling in the case of, for example, breast cancer.

EXPERIENCED MANAGEMENT TEAM

The management consists of Stefan Kröll, professor at Lund University, Johannes Swartling, who worked in companies such as SpectraCure, Gasporox, Neola Medical and NanoEcho, Tomas Kramar, former CEO of Siemens Healthineers Sweden, and Masoud Khayyami, well-known entrepreneur in life science companies in Lund.

Stefan Kröll, board member

Stefan Kröll is a professor of atomic physics and is part of the executive management team for the 12-year ~1000 SEK project WACQT (Wallenberg Center for Quantum Technology). Previous management assignments include Head of the Department of Physics, Lund University and member of the board of the Faculty of Engineering at Lund University.

Johannes Swartling, board member & CEO

Johannes has a PhD in physics from Lund University and is CTO at SpectraCure AB. He has extensive experience in commercializing research results in the role of CTO at SpectraCure and as former CTO at Gasporox and Neola Medical. He has been a board member of SpectraCure, Neola Medical and NanoEcho, among others

Masoud Khayyami, Chairman of the Board

Masoud has a PhD in applied biochemistry from Lund University and has solid experience from research in medical technology and biotechnology. He is CEO of SpectraCure AB. Masoud has entrepreneurial experience in companies such as Lumito AB, Gasporox AB and Prolight Diagnostics AB. Today, Masoud also works as CEO of Cardeon AB

Tomas Kramar, board member

Tomas has a master’s degree in chemical engineering from Lund University. He has over 40 years of experience from the life science industry and has previously worked, among other things, as CEO of Siemens Healthcare AB. Tomas has also worked at Abbott Laboratories, Becton Dickinson and Hoffmann La Roche. Tomas is chairman of Kramar Group AB and Percy Falk Cancer Foundation. He is also a board member of Cytocoat AB, Spectracure AB, Corsmed AB and Lundonia Biotech AB.